NCT02645227

Brief Summary

The present study is designed to evaluate the combined efficacy of Platelet Rich Fibrin (PRF) and 1.2% Rosuvastatin (RSV) with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 28, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 1, 2016

Completed
Last Updated

January 5, 2016

Status Verified

January 1, 2016

Enrollment Period

9 months

First QC Date

December 28, 2015

Last Update Submit

January 1, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • defect depth reduction (%)

    assessed in percentage

    Change from baseline to 9 months

Secondary Outcomes (4)

  • probing depth (mm)

    Change from baseline to 9 months

  • clinical attachment level (mm)

    Change from baseline to 9 months

  • modified sulcus bleeding index

    Change from baseline to 9 months

  • plaque index

    Change from baseline to 9 months

Study Arms (3)

Group 1

ACTIVE COMPARATOR

Open flap debridement (OFD)

Procedure: Open flap debridement (OFD)

Group 2

ACTIVE COMPARATOR

OFD with Platelet rich fibrin (PRF)

Procedure: OFD with Platelet rich fibrin (PRF)

Group 3

ACTIVE COMPARATOR

OFD with PRF and 1.2% Rosuvastatin

Procedure: OFD with PRF and 1.2% Rosuvastatin

Interventions

Oral prophylaxis followed by OFD for treating bone defect

Group 1

Oral prophylaxis followed by OFD with PRF placement into the bone defect

Group 2

Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect

Group 3

Eligibility Criteria

Age25 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Systemically healthy with CP diagnosis16 having probing depth (PD) ≥5mm, clinical attachment (CA) level ≥3mm and vertical bone loss ≥3mm on intraoral periapical radiographs (IOPAR) without any antibiotic or periodontal therapy in the last 6 months.

You may not qualify if:

  • History of statin allergy, statin therapy, any systemic condition or medication altering the periodontal condition, immune-compromised state, hematologic disorders, insufficient platelet count (\<200,000/mm3), aggressive periodontitis, substance/tobacco abuse and lactating and pregnant females.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Government Dental College and Research Institute

Bangalore, Karnataka, 560002, India

Location

MeSH Terms

Conditions

Chronic Periodontitis

Interventions

Prolactin-Releasing HormoneRosuvastatin Calcium

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hypothalamic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsNerve Tissue ProteinsProteinsSulfonamidesAmidesOrganic ChemicalsFluorobenzenesHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsSulfonesSulfur CompoundsPyrimidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Avani Pradeep, MDS

    Government Dental Colleege & Research Institute, Bangalore

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor and Head, Department of Periodontology

Study Record Dates

First Submitted

December 28, 2015

First Posted

January 1, 2016

Study Start

January 1, 2015

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

January 5, 2016

Record last verified: 2016-01

Locations